Physician profile
John V Fenice
NPI 1033138169
$10,287.16
in general payments reported to CMS, 2019-2025
42 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $631 · 2021: $1,909 · 2022: $1,718 · 2023: $1,799 · 2024: $1,625 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,794 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,794.19 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,085.44 | 2021-2025 | |
| Novo Nordisk INC | $1,870.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $877.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $552.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $494.24 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $473.09 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.57 | 2019-2025 | Relistor |
| Pfizer INC. | $354.87 | 2019-2024 | |
| Allergan, INC. | $280.08 | 2019-2021 | |
| Harmony Biosciences LLC | $261.53 | 2023-2024 | Wakix |
| Alkermes, INC. | $258.72 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Braeburn INC. | $244.39 | 2023-2025 | Brixadi |
| Indivior INC. | $242.18 | 2022-2025 | Sublocade |
| Astellas Pharma US INC | $232.52 | 2022-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $169.72 | 2020-2023 | Verquvo, Belsomra, Steglatro |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $166.54 | 2021 | |
| Ani Pharmaceuticals, INC. | $125.69 | 2025 | Purified Cortrophin Gel |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.33 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $107.01 | 2022-2023 | |
| Axsome Therapeutics, INC. | $93.00 | 2022-2023 | Sunosi |
| Biogen, INC. | $79.05 | 2021 | |
| Medtronic, INC. | $73.12 | 2022-2023 | Intellis Adaptivestim, Closurefast |
| Vanda Pharmaceuticals INC. | $69.52 | 2024-2025 | Fanapt, Hetlioz |
| Eisai INC. | $68.02 | 2021 | |
| Exact Sciences Corporation | $65.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $62.59 | 2021-2025 | Freestyle Libre 3 |
| Gilead Sciences, INC. | $61.72 | 2024-2025 | |
| Vbi Vaccine (Delaware) INC. | $51.95 | 2022-2023 | Prehevbrio |
| Sunovion Pharmaceuticals INC. | $46.19 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $45.26 | 2022 | |
| Neurocrine Biosciences, INC. | $40.92 | 2023 | Ingrezza |
| Seqirus USA INC | $35.27 | 2019-2020 | |
| Tactile Systems Technology INC | $26.23 | 2024 | Entre Plus, Flexitouch Plus |
| Ibsa Pharma INC. | $24.23 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.71 | 2022 | |
| Lundbeck LLC | $20.99 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.22 | 2025 | Jardiance |
| Dexcom, INC. | $17.45 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.55 | 2019 | |
| Alfasigma USA, INC. | $15.43 | 2020 | |
| Agios Pharmaceuticals, INC. | $14.33 | 2022 | |
| Biodelivery Sciences International, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fenice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.